178 related articles for article (PubMed ID: 18220567)
1. Strategies to in vitro assessment of major human CYP enzyme activities by using liquid chromatography tandem mass spectrometry.
Lahoz A; Donato MT; Castell JV; Gómez-Lechón MJ
Curr Drug Metab; 2008 Jan; 9(1):12-9. PubMed ID: 18220567
[TBL] [Abstract][Full Text] [Related]
2. Determination of major human cytochrome P450s activities in 96-well plates using liquid chromatography tandem mass spectrometry.
Lahoz A; Donato MT; Picazo L; Gómez-Lechón MJ; Castell JV
Toxicol In Vitro; 2007 Oct; 21(7):1247-52. PubMed ID: 17521862
[TBL] [Abstract][Full Text] [Related]
3. Reliable high-throughput method for inhibition assay of 8 cytochrome P450 isoforms using cocktail of probe substrates and stable isotope-labeled internal standards.
Kozakai K; Yamada Y; Oshikata M; Kawase T; Suzuki E; Haramaki Y; Taniguchi H
Drug Metab Pharmacokinet; 2012; 27(5):520-9. PubMed ID: 22498647
[TBL] [Abstract][Full Text] [Related]
4. Utility of mass spectrometry for in-vitro ADME assays.
Chu I; Nomeir AA
Curr Drug Metab; 2006 Jun; 7(5):467-77. PubMed ID: 16787156
[TBL] [Abstract][Full Text] [Related]
5. In vitro evaluation of metabolic drug-drug interactions: a descriptive and critical commentary.
Li AP
Curr Protoc Toxicol; 2007; Chapter 4():Unit 4.25. PubMed ID: 23045147
[TBL] [Abstract][Full Text] [Related]
6. Validation of higher-throughput high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry assays to conduct cytochrome P450s CYP2D6 and CYP3A4 enzyme inhibition studies in human liver microsomes.
Chu I; Favreau L; Soares T; Lin Cc; Nomeir AA
Rapid Commun Mass Spectrom; 2000; 14(4):207-14. PubMed ID: 10669878
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous Screening of Activities of Five Cytochrome P450 and Four Uridine 5'-Diphospho-glucuronosyltransferase Enzymes in Human Liver Microsomes Using Cocktail Incubation and Liquid Chromatography-Tandem Mass Spectrometry.
Lee B; Ji HK; Lee T; Liu KH
Drug Metab Dispos; 2015 Jul; 43(7):1137-46. PubMed ID: 25904760
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a liquid-chromatography high-resolution tandem mass spectrometry approach for quantification of nine cytochrome P450 (CYP) model substrate metabolites in an in vitro CYP inhibition cocktail.
Dinger J; Meyer MR; Maurer HH
Anal Bioanal Chem; 2014 Jul; 406(18):4453-64. PubMed ID: 24830396
[TBL] [Abstract][Full Text] [Related]
9. Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies.
Donato MT; Castell JV
Clin Pharmacokinet; 2003; 42(2):153-78. PubMed ID: 12537515
[TBL] [Abstract][Full Text] [Related]
10. Comparison of cytochrome P450 inhibition assays for drug discovery using human liver microsomes with LC-MS, rhCYP450 isozymes with fluorescence, and double cocktail with LC-MS.
Di L; Kerns EH; Li SQ; Carter GT
Int J Pharm; 2007 Apr; 335(1-2):1-11. PubMed ID: 17137735
[TBL] [Abstract][Full Text] [Related]
11. In Vitro Drug Metabolism Using Liver Microsomes.
Knights KM; Stresser DM; Miners JO; Crespi CL
Curr Protoc Pharmacol; 2016 Sep; 74():7.8.1-7.8.24. PubMed ID: 27636111
[TBL] [Abstract][Full Text] [Related]
12. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development.
Baranczewski P; Stańczak A; Sundberg K; Svensson R; Wallin A; Jansson J; Garberg P; Postlind H
Pharmacol Rep; 2006; 58(4):453-72. PubMed ID: 16963792
[TBL] [Abstract][Full Text] [Related]
13. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery.
Yan Z; Caldwell GW
Curr Top Med Chem; 2001 Nov; 1(5):403-25. PubMed ID: 11899105
[TBL] [Abstract][Full Text] [Related]
14. Assessment of cytochrome P450 induction in human hepatocytes using the cocktail strategy plus liquid chromatography tandem mass spectrometry.
Lahoz A; Donato MT; Picazo L; Castell JV; Gómez-Lechón MJ
Drug Metab Lett; 2008 Aug; 2(3):205-9. PubMed ID: 19356095
[TBL] [Abstract][Full Text] [Related]
15. Human hepatic cell cultures: in vitro and in vivo drug metabolism.
Gómez-Lechón MJ; Donato T; Ponsoda X; Castell JV
Altern Lab Anim; 2003; 31(3):257-65. PubMed ID: 15612868
[TBL] [Abstract][Full Text] [Related]
16. In vitro approaches to investigate cytochrome P450 activities: update on current status and their applicability.
Ong CE; Pan Y; Mak JW; Ismail R
Expert Opin Drug Metab Toxicol; 2013 Sep; 9(9):1097-113. PubMed ID: 23682848
[TBL] [Abstract][Full Text] [Related]
17. Prediction of cytochrome P450-mediated drug clearance in humans based on the measured activities of selected CYPs.
Gao J; Wang J; Gao N; Tian X; Zhou J; Fang Y; Zhang HF; Wen Q; Jia LJ; Zou D; Qiao HL
Biosci Rep; 2017 Dec; 37(6):. PubMed ID: 29054967
[TBL] [Abstract][Full Text] [Related]
18. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
Singh SS
Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effect of 5-fluorouracil on human cytochrome P(450) isoforms in human liver microsomes.
Park JY; Kim KA
Eur J Clin Pharmacol; 2003 Sep; 59(5-6):407-9. PubMed ID: 12904931
[TBL] [Abstract][Full Text] [Related]
20. Human hepatocytes in primary culture: the choice to investigate drug metabolism in man.
Gómez-Lechón MJ; Donato MT; Castell JV; Jover R
Curr Drug Metab; 2004 Oct; 5(5):443-62. PubMed ID: 15544436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
